Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Provided By GlobeNewswire
Last update: Aug 7, 2024
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody
Claudio Dansky Ullmann, M.D. named Chief Medical Officer
Cash and cash equivalents of $101.5 million as of June 30, 2024
Read more at globenewswire.comNASDAQ:CNTX (12/17/2025, 10:15:47 AM)
1.09
-0.01 (-0.91%)
Find more stocks in the Stock Screener
